These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 873093)

  • 41. Effect of two periods with intensified insulin treatment on B-cell function during the first 18 months of type 1 (insulin-dependent) diabetes mellitus.
    Krarup T; Madsbad S
    Diabete Metab; 1986 Oct; 12(5):256-60. PubMed ID: 3542618
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postprandial oscillatory patterns of blood glucose and insulin in NIDDM. Abnormal diurnal insulin secretion patterns and glucose homeostasis independent of obesity.
    Calles-Escandon J; Jaspan J; Robbins DC
    Diabetes Care; 1989; 12(10):709-14. PubMed ID: 2693010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preprogrammed intravenous insulin infusion in diabetic humans: metabolic consequences of altering meal size.
    Levy-Marchal C; Perlman K; Zinman B; Albisser AM
    Diabetes Care; 1986; 9(3):283-90. PubMed ID: 3525058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes.
    Turner RC; McCarthy ST; Holman RR; Harris E
    Br Med J; 1976 May; 1(6020):1252-4. PubMed ID: 1268654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pancreatic beta-cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal.
    Marchesini G; Melli A; Checchia GA; Mattioli L; Capelli M; Cassarani S; Zoli M; Pisi E
    Metabolism; 1985 Aug; 34(8):695-701. PubMed ID: 3894876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long term improvement in insulin response with gliclazide treatment.
    Bodansky HJ; Medback S; Cudworth AG; Rees LH; de Silva RS
    Diabete Metab; 1982 Dec; 8(4):319-22. PubMed ID: 6761187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus.
    Nicolau GY; Haus E; Lakatua DJ; Bogdan C; Petrescu E; Sackett-Lundeen L; Stelea S; Stelea P
    Endocrinologie; 1984; 22(1):3-16. PubMed ID: 6369501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma C-peptide in long-standing type 1 diabetics with and without microvascular disease.
    Bodansky HJ; Medbak S; Drury PL; Cudworth AG
    Diabete Metab; 1981 Dec; 7(4):265-9. PubMed ID: 7333406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human C-peptide in normal and diabetic subjects.
    Heding LG; Rasmussen SM
    Diabetologia; 1975 Jun; 11(3):201-6. PubMed ID: 1149953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twenty-four hour profiles of plasma C-peptide in type 1 (insulin-dependent) diabetic children.
    Werther GA; Turner RC; Jenkins PA; Baum JD
    Diabetologia; 1982 Apr; 22(4):245-9. PubMed ID: 7047271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus.
    Starke A; Keck E; Berger M; Zimmermann H
    Diabetologia; 1981 May; 20(5):547-52. PubMed ID: 7026328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of cortisol circadian variations on insulin need and delivery in insulin-dependent diabetics. Assessment by the artificial beta cell.
    Altomare E; Moulin JP; Tavares S; Bourelly N; Lassmann V; Vague P
    Horm Metab Res Suppl; 1979; (8):110-5. PubMed ID: 395065
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of acetylsalicylic acid on blood glucose, plasma FFA, glycerol, 3-hydroxybutyrate, alanine, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetics.
    Giugliano D; Luyckx AS; Lefebvre PJ
    Diabete Metab; 1980 Mar; 6(1):39-46. PubMed ID: 6989660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects.
    Levy JC; Rudenski A; Burnett M; Knight R; Matthews DR; Turner RC
    Diabetologia; 1991 Jul; 34(7):488-99. PubMed ID: 1916054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients.
    Larsen JJ; Dela F; Kjaer M; Galbo H
    Diabetologia; 1997 Apr; 40(4):447-53. PubMed ID: 9112022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Added benfluorex in obese insulin-requiring type 2 diabetes.
    Leutenegger M; Bauduceau B; Brun JM; Guillon-Metz F; Martin C; Nicolino-Peltier C; Richard JL; Vannereau D
    Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma insulin and C-peptide responses to oral glucose in newly diagnosed diabetics in north-western Tanzania.
    Ahren B; Corrigan CB; Alberti KG
    East Afr Med J; 1988 Dec; 65(12):847-51. PubMed ID: 3069450
    [No Abstract]   [Full Text] [Related]  

  • 58. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.
    Andrews WJ; Vasquez B; Nagulesparan M; Klimes I; Foley J; Unger R; Reaven GM
    Diabetes; 1984 Jul; 33(7):634-42. PubMed ID: 6376219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
    Frias JP; Yu JG; Kruszynska YT; Olefsky JM
    Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.